



## SASKATCHEWAN FORMULARY BULLETIN

### Update to the 62nd Edition of the Saskatchewan Formulary

**Change from Exception Drug Status Listing to Full Formulary Benefit:**

- insulin lispro, injection solution, 100U/mL (5x3mL) (10mL) (Humalog-LIL) (Humalog Cartridge-LIL) (Humalog Kwikpen-LIL)
- pantoprazole sodium, enteric-coated tablet, 20mg (Sandoz Pantoprazole-SDZ) (Apo-Pantoprazole-APX) (Teva-Pantoprazole-TEV) (Ran-Pantoprazole-RAN) (Jamp-Pantoprazole-JPC) (Pantoprazole-SIV); 40mg (Pantoloc-TAK) (Apo-Pantoprazole-APX) (Teva-Pantoprazole-TEV)(Ran-Pantoprazole-RAN) (CO Pantoprazole-COB) (Mylan-Pantoprazole-MYL)(pms-Pantoprazole-PMS) (Sandoz Pantoprazole-SDZ) (Pantoprazole-SAN) (Pantoprazole-SIV) (Mar-Pantoprazole-MPI)(Jamp-Pantoprazole-JPC) (Auro-Pantoprazole-API) (Mint-Pantoprazole-MNT)(Abbott-Pantoprazole-ABB)

**New Exception Drug Status (EDS) Listings Effective July 1, 2014 according to the following criteria:**

- perampanel, tablet, 2mg, 4mg, 6mg, 8mg, 10mg, 12mg (Fycompa-EIS)

For the adjunctive treatment of refractory partial-onset seizures in patients who meet all of the following criteria:

- Are currently receiving two or more antiepileptic drugs; AND.
- Less costly antiepileptic drugs are ineffective or inappropriate; AND
- The medication is being used under the direction of a neurologist.

*Note: Patients should have tried and failed at least two less costly antiepileptic drugs*

**New Exception Drug Status (EDS) Listings Effective July 1, 2014 according to the following criteria:**

- sitagliptin/metformin, extended release tablet, 50mg/1,000mg (Janumet XR-MRK)

For the convenience of patients who have been stabilized on metformin and sitagliptin.

**Please Note:** *These products should be used in patients with diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea, and for whom insulin is not an option.*

**New Non-Interchangeable Exception Drug Status (EDS) Listing Effective July 1, 2014 according to existing criteria:**

- **epoprostenol sodium, powder for injection, 0.5mg/10ml vial, 1.5mg/10ml vial (Caripul-ACT)**  
For treatment of pulmonary hypertension on the recommendation of a specialist.  
*Please contact the Drug Plan for billing information.*
- **epoprostenol sodium, Caripul Diluent (normal saline/sterile water)**  
Patient must have a prescription for Caripul
- **epoprostenol sodium, Per Diem Supplies (Caripul Supp/Per Diem)**  
Patient must have a prescription for Caripul

**Revised Exception Drug Status Criteria (see bold italicized portion):**

- **tocilizumab, solution for IV infusion, 20mg/mL (4mL vial, 10mL vial, 20mL vial) (Actemra-HLR)**
  - a) for treatment of moderate to severe active rheumatoid arthritis, ***alone or*** in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs), ***in patients who have failed to respond to an adequate trial of DMARDs.***  
Patients should be assessed after 16 weeks of treatment and therapy continued only if there is a clinical response to treatment.  
*Actemra should not be used concomitantly with TNF alpha inhibitors.*  
*This product should be used in consultation with a specialist in this area.*
  - b) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients two years of age and older who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids (with or without methotrexate), due to intolerance or lack of efficacy.  
*Actemra should not be used concomitantly with TNF alpha inhibitors.*  
*This product should be used in consultation with a specialist in this area.*

**Drugs Reviewed and Not Approved for Listing in the Saskatchewan Formulary:**

- **oxycodone HCL, controlled-release tablet, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg (OxyNeo-PFR)** for treatment of chronic non-cancer pain

**Saskatchewan Ministry of Health  
Drug Plan and Extended Benefits Branch  
2<sup>nd</sup> Floor, 3475 Albert Street  
Regina, Saskatchewan S4S 6X6  
(306) 787-3317  
1-800-667-7581**

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Ministry of Health. Inquiries should be directed to the address or telephone numbers shown at left.